Current Role of SLGT2 Inhibitors in the Management of the Whole Spectrum of Heart Failure: Focus on Dapagliflozin
Heart failure (HF) is associated with a high morbidity and mortality burden. In light of more recent evidence, SGLT2 inhibitors are currently recommended as first-line therapy in managing patients with HF, regardless of ejection fraction, to reduce HF burden. The DAPA-HF and DELIVER trials, and part...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-10-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/12/21/6798 |
| _version_ | 1797631717562908672 |
|---|---|
| author | Carlos Escobar Domingo Pascual-Figal Luis Manzano Julio Nuñez Miguel Camafort |
| author_facet | Carlos Escobar Domingo Pascual-Figal Luis Manzano Julio Nuñez Miguel Camafort |
| author_sort | Carlos Escobar |
| collection | DOAJ |
| description | Heart failure (HF) is associated with a high morbidity and mortality burden. In light of more recent evidence, SGLT2 inhibitors are currently recommended as first-line therapy in managing patients with HF, regardless of ejection fraction, to reduce HF burden. The DAPA-HF and DELIVER trials, and particularly, the pooled analysis of both studies, have shown that dapagliflozin significantly reduces the risk of cardiovascular death, all-cause death, total HF hospitalizations, and MACE in the whole spectrum of HF, with sustained benefits over time. Recent data have shown that the full implementation of dapagliflozin in clinical practice would translate into a robust reduction in hospitalizations for HF and death in real-life populations. Many pathophysiological mechanisms have been involved in these benefits, particularly the positive effects of dapagliflozin on reversing cardiac (atrial and ventricular) remodeling, reducing cardiac fibrosis and inflammation, and improving endothelial dysfunction. In this manuscript, we reviewed from a practical point of view the role of dapagliflozin in the management of the whole spectrum of patients with HF. |
| first_indexed | 2024-03-11T11:27:15Z |
| format | Article |
| id | doaj.art-5440e7c159ae4fb59b3c8ba11c1d82b4 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-11T11:27:15Z |
| publishDate | 2023-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-5440e7c159ae4fb59b3c8ba11c1d82b42023-11-10T15:06:29ZengMDPI AGJournal of Clinical Medicine2077-03832023-10-011221679810.3390/jcm12216798Current Role of SLGT2 Inhibitors in the Management of the Whole Spectrum of Heart Failure: Focus on DapagliflozinCarlos Escobar0Domingo Pascual-Figal1Luis Manzano2Julio Nuñez3Miguel Camafort4Cardiology Department, University Hospital La Paz, 28046 Madrid, SpainCardiology Department, Hospital Clinico Universitario Virgen de la Arrixaca, 30120 Murcia, SpainInternal Medicine Department, University Hospital Ramon y Cajal, Alcala de Henares University, 28034 Madrid, SpainCardiology Department, University Hospital Clínico of Valencia, Instituto de Investigación Sanitaria (INCLIVA), 46010 Valencia, SpainInternal Medicine Department, Hospital Clinic, University of Barcelona, 08036 Barcelona, SpainHeart failure (HF) is associated with a high morbidity and mortality burden. In light of more recent evidence, SGLT2 inhibitors are currently recommended as first-line therapy in managing patients with HF, regardless of ejection fraction, to reduce HF burden. The DAPA-HF and DELIVER trials, and particularly, the pooled analysis of both studies, have shown that dapagliflozin significantly reduces the risk of cardiovascular death, all-cause death, total HF hospitalizations, and MACE in the whole spectrum of HF, with sustained benefits over time. Recent data have shown that the full implementation of dapagliflozin in clinical practice would translate into a robust reduction in hospitalizations for HF and death in real-life populations. Many pathophysiological mechanisms have been involved in these benefits, particularly the positive effects of dapagliflozin on reversing cardiac (atrial and ventricular) remodeling, reducing cardiac fibrosis and inflammation, and improving endothelial dysfunction. In this manuscript, we reviewed from a practical point of view the role of dapagliflozin in the management of the whole spectrum of patients with HF.https://www.mdpi.com/2077-0383/12/21/6798dapagliflozinheart failurehospitalizationmortality |
| spellingShingle | Carlos Escobar Domingo Pascual-Figal Luis Manzano Julio Nuñez Miguel Camafort Current Role of SLGT2 Inhibitors in the Management of the Whole Spectrum of Heart Failure: Focus on Dapagliflozin Journal of Clinical Medicine dapagliflozin heart failure hospitalization mortality |
| title | Current Role of SLGT2 Inhibitors in the Management of the Whole Spectrum of Heart Failure: Focus on Dapagliflozin |
| title_full | Current Role of SLGT2 Inhibitors in the Management of the Whole Spectrum of Heart Failure: Focus on Dapagliflozin |
| title_fullStr | Current Role of SLGT2 Inhibitors in the Management of the Whole Spectrum of Heart Failure: Focus on Dapagliflozin |
| title_full_unstemmed | Current Role of SLGT2 Inhibitors in the Management of the Whole Spectrum of Heart Failure: Focus on Dapagliflozin |
| title_short | Current Role of SLGT2 Inhibitors in the Management of the Whole Spectrum of Heart Failure: Focus on Dapagliflozin |
| title_sort | current role of slgt2 inhibitors in the management of the whole spectrum of heart failure focus on dapagliflozin |
| topic | dapagliflozin heart failure hospitalization mortality |
| url | https://www.mdpi.com/2077-0383/12/21/6798 |
| work_keys_str_mv | AT carlosescobar currentroleofslgt2inhibitorsinthemanagementofthewholespectrumofheartfailurefocusondapagliflozin AT domingopascualfigal currentroleofslgt2inhibitorsinthemanagementofthewholespectrumofheartfailurefocusondapagliflozin AT luismanzano currentroleofslgt2inhibitorsinthemanagementofthewholespectrumofheartfailurefocusondapagliflozin AT julionunez currentroleofslgt2inhibitorsinthemanagementofthewholespectrumofheartfailurefocusondapagliflozin AT miguelcamafort currentroleofslgt2inhibitorsinthemanagementofthewholespectrumofheartfailurefocusondapagliflozin |